http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Lee, Hye Won,Chung, Sook Hee,Moon, Chang Mo,Che, Xiumei,Kim, Seung Won,Park, Soo Jung,Hong, Sung Pil,Kim, Tae Il,Kim, Won Ho,Cheon, Jae Hee Williams & Wilkins Co 2016 Medicine Vol.95 No.23
<▼1><P>Supplemental Digital Content is available in the text</P></▼1><▼2><P><B>Abstract</B></P><P>Genetic variants in <I>IL12B</I>, encoding the p40 subunit common in interleukin-12 (IL-12) and interleukin-23, were identified as the susceptibility loci for inflammatory bowel disease (IBD). This study aimed to identify the correlation of serum IL-12B expression with disease activity in patients with IBD and evaluate the possibility of IL-12B as a biomarker for assessing inflammatory status in IBD.</P><P>A total of 102 patients with IBD, including 38, 32, and 32 patients with Crohn's disease (CD), ulcerative colitis (UC), and intestinal Behçet's disease (intestinal BD), respectively, were included. The clinical and laboratory data from the patients were collected at the time of serum IL-12B measurement. Serum IL-12B levels were measured using an enzyme-linked immunosorbent assay.</P><P>The median IL-12B levels in patients with CD, UC, and intestinal BD were significantly higher than those in controls (1.87, 2.74, and 2.73 pg/mL, respectively, vs. 1.42 pg/mL, all <I>P</I> <0.05). IL-12B concentrations were associated with disease activity in patients with UC and intestinal BD but not in those with CD. IL-12B levels were increased with increasing disease activity in patients with UC (<I>P</I> <0.001). Likewise, patients with active intestinal BD had higher IL-12B levels than those without active disease (<I>P</I> = 0.008). IL-12B levels were correlated with the endoscopic disease activity of UC (<I>P</I> = 0.002) and intestinal BD (<I>P</I> = 0.001) but not that of CD.</P><P>Serum IL-12B levels were significantly correlated with clinical and endoscopic disease activity in patients with UC and intestinal BD, suggesting its potential use as a biomarker for assessing disease activity in these patients.</P></▼2>
Abdal-hay, Abdalla,Memic, Adnan,Hussein, Kamal H.,Oh, Yi Seul,Fouad, Mohamed,Al-Jassir, Fawzi F.,Woo, Heung-Myong,Morsi, Yosry,Mo, Xiumei,Ivanovski, Saš,o Elsevier 2017 European polymer journal Vol.96 No.-
<P><B>Abstract</B></P> <P>Three dimensional (3D) constructs for vascular tissue engineering applications require scaffolds with highly porous architectures, high biocompatibility and mechanical stability. In this paper, composite fibrous tubular scaffolds composed of different ratios of poly(epsilon-caprolactone) (PCL) and polyamide-6 (PA-6) were simultaneously deposited layer by layer by employing the air jet spinning (AJS) textile technique. Specifically, we report on the optimal parameters for the fabrication of composite porous scaffolds that allow for precise control over the general scaffold architecture, as well as the physical and mechanical properties of the scaffolds. In vitro cell culture study was performed to investigate the influence of polymer composition and scaffold architecture on the adhesion of EA.hy926 human endothelial cells onto the fabricated scaffolds. The cell culture results indicated that a composite scaffold with low PA-6 fibrous content is the most promising substrate for EA.hy926 adhesion and proliferation. Based on the present findings, these highly porous composite tubular constructs support endothelial cell migration and cellular infiltration, and hence represent promising nano-fibrous scaffolds for vascular tissue engineering.</P> <P><B>Highlights</B></P> <P> <UL> <LI> PCL/Nylon 6 dual) fibrous 3D tissue scaffolds were synthesized for vascular grafts. </LI> <LI> Highly and tunable hybrid porous fibrous tissue scaffold was obtained by AJS. </LI> <LI> EA.hy926 EC was sued to determine the biocompatibility of tissue scaffolds. </LI> <LI> Dual scaffold provided a favorable attachment and proliferation of EA.hy926 human EC. </LI> <LI> Dual scaffold at low N6 content induced highest biocompatibility compared to others. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>